Eli Lilly (NYSE: LLY) has emerged as one of the hottest stocks in the GLP-1 realm -- underscored by its combination of ...

Learn how chemists have invented a new technology to solve the shortage of GLP-1 medications by improving drug delivery.

Weight loss is a key effect of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), but these drugs may also provide liver ...

Studies show that high-protein diets can help GLP-1 (glucagon-like peptide 1) medication users be more successful in their ...

Glucagon-like peptide-1 (GLP-1) receptor agonists are peptide-based therapeutics for treating diabetes and for weight loss.

Patients with diabetes or obesity receiving GLP-1 RAs are unlikely to experience an increase in the already low rates of ...

Employers, including Express Scripts parent company Cigna, seek to manage GLP-1 costs through programs administered by the ...

Compounding pharmacies have filed a lawsuit against the Food and Drug Administration following its removal of Novo Nordisk's semaglutide, a type of glucagon-like peptide-1, from a drug shortage list.

However, for crude incidence rates there was an increased incidence of suicidality with GLP-1 receptor agonist vs DPP-4 inhibitor use; 3.9 vs 1.8 per 1000 person-years. HealthDay News — Glucagon ...

Biocon Limited, an innovation-led global biopharmaceutical company, announced the launch of its GLP-1 peptide, Liraglutide, for diabetes and obesity, in the United Kingdom (UK). The drug-device ...

CordenPharma provides large-scale peptide manufacturing for the Dual GLP-1/GIP Receptor Agonist drug substance of VK2735. CordenPharma provides fill-finish for the drug candidate's subcutaneous ...